Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ovarian Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 26 articles: HTML format Text format

Single Articles

March 2018
1. COLOMBO N, Huang G, Scambia G, Chalas E, et al
   Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
   J Clin Oncol. 2018 Mar 20:JCO2017762781. doi: 10.1200/JCO.2017.76.2781.
   PubMed     Text format     Abstract available
   
   
   October 2017
2. BERCHUCK A, Secord AA, Moss HA, Havrilesky LJ, et al
   Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
   J Clin Oncol. 2017 Oct 26:JCO2017745752. doi: 10.1200/JCO.2017.74.5752.
   PubMed     Text format    
   
   
   August 2017
3. PIGNATA S, Scambia G, Bologna A, Signoriello S, et al
   Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
   J Clin Oncol. 2017 Aug 21:JCO2017734293. doi: 10.1200/JCO.2017.73.4293.
   PubMed     Text format     Abstract available
   
   
   
4. CHILDERS CP, Childers KK, Maggard-Gibbons M, Macinko J, et al
   National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
   J Clin Oncol. 2017 Aug 18:JCO2017736314. doi: 10.1200/JCO.2017.73.6314.
   PubMed     Text format     Abstract available
   
   
   July 2017
5. SAMIMI G, Bernardini MQ, Brody LC, Caga-Anan CF, et al
   Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
   J Clin Oncol. 2017;35:2329-2337.
   PubMed     Text format     Abstract available
   
   
   
6. WILLMANN JK, Bonomo L, Carla Testa A, Rinaldi P, et al
   Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.
   J Clin Oncol. 2017;35:2133-2140.
   PubMed     Text format     Abstract available
   
   
   May 2017
7. BERCHUCK A, Havrilesky LJ, Kauff ND
   Is There a Role for Ovarian Cancer Screening in High-Risk Women?
   J Clin Oncol. 2017;35:1384-1386.
   PubMed     Text format    
   
   
   April 2017
8. CHRISTIE EL, Fereday S, Doig K, Pattnaik S, et al
   Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
   J Clin Oncol. 2017;35:1274-1280.
   PubMed     Text format     Abstract available
   
   
   
9. KONECNY GE
   Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.
   J Clin Oncol. 2017;35:1151-1153.
   PubMed     Text format    
   
   
   
10. SHAIKH F, Cullen JW, Olson TA, Pashankar F, et al
    Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2017;35:1203-1210.
    PubMed     Text format     Abstract available
    
    
    
11. LHEUREUX S, Bruce JP, Burnier JV, Karakasis K, et al
    Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    J Clin Oncol. 2017;35:1240-1249.
    PubMed     Text format     Abstract available
    
    
    
12. TAYLOR JS, Rajan SS, Zhang N, Meyer LA, et al
    End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer.
    J Clin Oncol. 2017 Apr 7:JCO2016702894. doi: 10.1200/JCO.2016.70.2894.
    PubMed     Text format     Abstract available
    
    
    
13. GERSHENSON DM, Bodurka DC, Coleman RL, Lu KH, et al
    Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
    J Clin Oncol. 2017;35:1103-1111.
    PubMed     Text format     Abstract available
    
    
    
14. MOORE KN, Martin LP, O'Malley DM, Matulonis UA, et al
    Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    J Clin Oncol. 2017;35:1112-1118.
    PubMed     Text format     Abstract available
    
    
    February 2017
15. ROSENTHAL AN, Fraser LS, Philpott S, Manchanda R, et al
    Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    J Clin Oncol. 2017 Feb 27:JCO2016699330. doi: 10.1200/JCO.2016.69.9330.
    PubMed     Text format     Abstract available
    
    
    January 2017
16. FOTOPOULOU C, Sehouli J, Aletti G, Harter P, et al
    Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.
    J Clin Oncol. 2017 Jan 9:JCO2016710723.
    PubMed     Text format    
    
    
    December 2016
17. RUTTEN MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, et al
    Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Dec 28:JCO2016692962.
    PubMed     Text format     Abstract available
    
    
    
18. COPUR MS, Gauchan D, Ramaekers R, Crockett D, et al
    Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer.
    J Clin Oncol. 2016 Dec 28:JCO2016707125.
    PubMed     Text format    
    
    
    
19. LIU JF, Ray-Coquard I, Selle F, Poveda AM, et al
    Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
    J Clin Oncol. 2016;34:4345-4353.
    PubMed     Text format     Abstract available
    
    
    
20. SCHRAM AM, Iasonos A, Hyman DM
    Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2016;34:4312-4314.
    PubMed     Text format    
    
    
    
21. LEIJEN S, van Geel RM, Sonke GS, de Jong D, et al
    Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
    J Clin Oncol. 2016;34:4354-4361.
    PubMed     Text format     Abstract available
    
    
    March 2016
22. TUNG N, Lin NU, Kidd J, Allen BA, et al
    Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO650747.
    PubMed     Text format     Abstract available
    
    
    January 2016
23. HORN C, Campbell G, Hagan T, Bovbjerg DH, et al
    Associations between peripheral neuropathy and nausea/vomiting in survivors of ovarian cancer: Evidence of persistent vagal neuropathies?
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available
    
    
    
24. ANGARITA A, Cristello A, Lippitt M, Nickles Fader A, et al
    The "little big things": A qualitative study of ovarian cancer survivors and their experiences with the health care system.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available
    
    
    
25. GASPARRI ML, Crispino S, La Russa C, Marchetti C, et al
    A 10-year age-related survival analysis on cytoreductive surgery in stage IIIC-IV ovarian cancer: Elderly versus younger women.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available
    
    
    
26. BLACKMON JE, Recklitis CJ, Wright AA
    Preliminary results from the Sexual Therapy and Rehabilitation after Treatment for Ovarian Cancer (START-OC) study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: